LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a

Cancer Medicine

Volumn 5, Issue 12, 2016, Pages 3512-3519

  Liu, Hong Tao ^a   Fang, Lei ^a   Cheng, Yu Xia ^a   Sun, Qing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Growth; methylation; miR 146a; prostate cancer; PVT1

Indexed keywords

LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA PVT1; MICRORNA 146A; UNCLASSIFIED DRUG; MICRORNA; MIRN146 MICRORNA, HUMAN; PVT1 LONG-NON-CODING RNA, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MALE; MICRORNAS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RNA, LONG NONCODING;

EID: 84996957387     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.900     Document Type: Article

References (39)

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9–29.
2. Bilusic, M., C. Heery, and R. A. Madan. 2011. Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine 29:6485–6497.
3. Siegel, R., C. DeSantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, et al. 2012. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 62:220–241.
4. Xue, G., Z. Ren, Y. Chen, J. Zhu, Y. Du, D. Pan, et al. 2015. A feedback regulation between mir-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation. Cancer Lett. 361:121–127.
5. Roehl, K. A., M. Han, C. G. Ramos, J. A. Antenor, and W. J. Catalona 2004. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J. Urol. 172:910–914.
6. Thompson, I., J. B. Thrasher, G. Aus, A. L. Burnett, E. D. Canby-Hagino, M. S. Cookson, et al. 2007. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177:2106–2131.
7. Boorjian, S. A., J. A. Eastham, M. Graefen, B. Guillonneau, R. J. Karnes, J. W. Moul, et al. 2012. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur. Urol. 61:664–675.
8. Zhang, Z., Z. Zhu, B. Zhang, W. Li, X. Li, X. Wu, et al. 2014. Frequent mutation of rs13281615 and its association with pvt1 expression and cell proliferation in breast cancer. J. Genet. Genomics 41:187–195.
9. Y. R. Yang, S. Z. Zang, C. L. Zhong, Y. X. Li, S. S. Zhao, and X. J. Feng. 2014. Increased expression of the lncrna pvt1 promotes tumorigenesis in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 7:6929–6935.
10. Ding, C., Z. Yang, Z. Lv, C. Du, H. Xiao, C. Peng, et al. 2015. Long non-coding rna pvt1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol. Lett. 9:955–963.
11. Ding, J., D. Li, M. Gong, J. Wang, X. Huang, T. Wu, et al. 2014. Expression and clinical significance of the long non-coding rna pvt1 in human gastric cancer. OncoTargets Ther. 7:1625–1630.
12. Takahashi, Y., G. Sawada, J. Kurashige, R. Uchi, T. Matsumura, H. Ueo, et al. 2014. Amplification of pvt-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br. J. Cancer 110:164–171.
13. Fang, X. Y., H. F. Pan, R. X. Leng, and D. Q. Ye 2015. Long noncoding rnas: Novel insights into gastric cancer. Cancer Lett. 356:357–366.
14. Guan, Y., W. L. Kuo, J. L. Stilwell, H. Takano, A. V. Lapuk, J. Fridlyand, et al. 2007. Amplification of pvt1 contributes to the pathophysiology of ovarian and breast cancer. Clin. Cancer Res. 13:5745–5755.
15. Soubra, A., B. Konety, and A. Bagchi. 2015. Mp61-06 increased pvt1 expression correlates with advanced stage and hormone resistance of prostate cancer. J. Urol. 193:e748–e749.
16. Meyer, K. B., A. T. Maia, M. O'Reilly, M. Ghoussaini, R. Prathalingam, P. Porter-Gill, et al. 2011. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with pvt1 expression. PLoS Genet. 7:e1002165.
17. Fu, B., P. Song, M. Lu, B. Wang, and Q. Zhao. 2014. The association between mir-146a gene rs2910164 polymorphism and gastric cancer risk: A meta-analysis. Biomed. Pharmacother. 68:923–928.
18. Xu, T., Y. Zhu, Q. K. Wei, Y. Yuan, F. Zhou, Y. Y. Ge, et al. 2008. A functional polymorphism in the mir-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29:2126–2131.
19. Jeon, H. S., Y. H. Lee, S. Y. Lee, J. A. Jang, Y. Y. Choi, S. S. Yoo, et al. 2014. A common polymorphism in pre-microrna-146a is associated with lung cancer risk in a korean population. Gene 534:66–71.
20. Pastrello, C., J. Polesel, L. Della Puppa, A. Viel, and R. Maestro. 2010. Association between hsa-mir-146a genotype and tumor age-of-onset in brca1/brca2-negative familial breast and ovarian cancer patients. Carcinogenesis 31:2124–2126.
21. Mittal, R. D., R. Gangwar, G. P. George, T. Mittal, and R. Kapoor. 2011. Investigative role of pre-micrornas in bladder cancer patients: A case–control study in north india. DNA Cell Biol. 30:401–406.
22. Xu, B., N. H. Feng, P. C. Li, J. Tao, D. Wu, Z. D. Zhang, et al. 2010. A functional polymorphism in pre-mir-146a gene is associated with prostate cancer risk and mature mir-146a expression in vivo. Prostate 70:467–472.
23. George, G. P., R. Gangwar, R. K. Mandal, S. N. Sankhwar, and R. D. Mittal. 2011. Genetic variation in microrna genes and prostate cancer risk in north indian population. Mol. Biol. Rep. 38:1609–1615.
24. Nikolic´, Z. Z., D. L. S. Pavic´evic´, V. D. Vukotic´, S. M. Tomovic´, S. J. Cerovic´, N. Filipovic´, et al. 2014. Association between genetic variant in hsa-mir-146a gene and prostate cancer progression: Evidence from serbian population. Cancer Causes Control 25:1571–1575.
25. Tomokuni, A., H. Eguchi, Y. Tomimaru, et al. 2011. Mir-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 414:675–680.
26. Wang, X., S. Tang, S. Y. Le, R. Lu, J. S. Rader, C. Meyers, and Z. M. Zheng. 2008. Aberrant expression of oncogenic and tumor-suppressive micrornas in cervical cancer is required for cancer cell growth. PLoS ONE 3:e2557.
27. Bhaumik, D., G. Scott, S. Schokrpur, C. K. Patil, J. Campisi, and C. C. Benz. 2008. Expression of microrna-146 suppresses nf-κb activity with reduction of metastatic potential in breast cancer cells. Oncogene 27:5643–5647.
28. Hurst, D. R., M. D. Edmonds, G. K. Scott, C. C. Benz, K. S. Vaidya, and D. R. Welch. 2009. Breast cancer metastasis suppressor 1 up-regulates mir-146, which suppresses breast cancer metastasis. Cancer Res. 69:1279–1283.
29. Li, Y., T. G. VandenBoom, Z. Wang, D. Kong, S. Ali, P. A. Philip, et al. 2010. Mir-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70:1486–1495.
30. Mei, J., R. Bachoo, and C. L. Zhang. 2011. Microrna-146a inhibits glioma development by targeting notch1. Mol. Cell. Biol. 31:3584–3592.
31. Yao, Q., Z. Cao, C. Tu, Y. Zhao, H. Liu, and S. Zhang. 2013. Microrna-146a acts as a metastasis suppressor in gastric cancer by targeting wasf2. Cancer Lett. 335:219–224.
32. Lin, S. L., A. Chiang, D. Chang, and S. Y. Ying. 2008. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14:417–424.
33. Hanoun, N., Y. Delpu, A. A. Suriawinata, B. Bournet, C. Bureau, J. Selves, et al. 2010. The silencing of microrna 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 56:1107–1118.
34. Ali, S., A. Ahmad, A. Aboukameel, A. Ahmed, B. Bao, S. Banerjee, et al. 2014. Deregulation of mir-146a expression in a mouse model of pancreatic cancer affecting egfr signaling. Cancer Lett. 351:134–142.
35. Lyko, F., and R. Brown. 2005. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl Cancer Inst. 97:1498–1506.
36. Hu, C., and J. Zhou. 2009. Abnormality of DNA methylation modification and lung cancer. International Journal of Pathology and Clinical Medicine 5:398–402.
37. Beck-Engeser, G. B., A. M. Lum, K. Huppi, N. J. Caplen, B. B. Wang, and M. Wabl. 2008. Pvt1-encoded micrornas in oncogenesis. Retrovirology 5:4.
38. Alvarez, M. L., M. Khosroheidari, E. Eddy, and J. Kiefer. 2013. Role of microrna 1207-5p and its host gene, the long non-coding rna pvt1, as mediators of extracellular matrix accumulation in the kidney: Implications for diabetic nephropathy. PLoS ONE 8:e77468.
39. Zhang, X. W., P. Bu, L. Liu, X. Z. Zhang, and J. Li. 2015. Overexpression of long non-coding rna pvt1 in gastric cancer cells promotes the development of multidrug resistance. Biochem. Biophys. Res. Commun. 462:227–232.